Fischer Medical Ventures Ltd (IN:FISCHER)
:FISCHER
Want to see IN:FISCHER full AI Analyst Report?
Top Page
Fischer Medical Ventures Ltd
(FISCHER)
Select Model
Select Model
Rating:51Neutral
Price Target:
₹34.00
▼(-22.14% Downside)
Action:Reiterated
Date:06/07/26
The score is held back primarily by persistent and significant negative operating/free cash flow despite improved reported profitability, and by bearish technical signals with the stock trading below key moving averages. A high P/E with only a modest dividend yield further limits support, while the main positive is the sharp FY2026 step-up in revenue and margins.
Positive Factors
Sharp Revenue Step-up
FY2026's large revenue increase demonstrates the company has achieved material scale versus prior years. A sustained higher top line provides more room to absorb fixed costs, supports investment in product and distribution, and underpins medium-term earnings durability if growth persists.
Negative Factors
Persistent Cash Burn
Deeply negative operating and free cash flows in consecutive years show earnings are not translating into cash. This structural cash burn raises reliance on external financing, increases dilution or refinancing risk, and threatens sustainability of growth if cash conversion drivers aren't corrected.
Read all positive and negative factors
Positive Factors
Negative Factors
Sharp Revenue Step-up
FY2026's large revenue increase demonstrates the company has achieved material scale versus prior years. A sustained higher top line provides more room to absorb fixed costs, supports investment in product and distribution, and underpins medium-term earnings durability if growth persists.
Read all positive factors
Fischer Medical Ventures Ltd (FISCHER) vs. iShares MSCI India ETF (INDA)
Market Cap
₹23.48B
Dividend Yield0.01%
Average Volume (3M)267.56K
Price to Earnings (P/E)75.3
Beta (1Y)0.25
Revenue Growth178.75%
EPS Growth2120.65%
CountryIN
Employees40
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.22
Shares Outstanding648,515,440
10 Day Avg. Volume611,655
30 Day Avg. Volume267,556
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)6.83
Price to Sales (P/S)8.52
P/FCF Ratio-20.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fischer Medical Ventures Ltd Business Overview & Revenue Model
Company Description
Fischer Medical Ventures Limited, established in 1993 and headquartered in Chennai, India, is a global provider of medical equipment. The company's operations encompass the manufacturing, distribution, leasing, and maintenance of a wide array of m...
Fischer Medical Ventures Ltd Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.35B | 3.09B | 1.11B | 209.81M | 1.79M | 0.00 |
| Gross Profit | 302.73M | 949.12M | 191.09M | 45.27M | 1.79M | 0.00 |
| EBITDA | 212.21M | 430.83M | 42.58M | 23.61M | 152.00K | -1.89M |
| Net Income | 152.08M | 312.41M | 12.08M | 18.38M | -365.00K | -2.33M |
Balance Sheet | ||||||
| Total Assets | 4.68B | 6.72B | 4.57B | 863.22M | 3.54M | 1.90M |
| Cash, Cash Equivalents and Short-Term Investments | 428.70M | 250.46M | 2.51B | 379.46M | 358.00K | 156.00K |
| Total Debt | 370.08M | 1.07B | 853.72M | 16.77M | 11.43M | 3.89M |
| Total Liabilities | 1.07B | 2.86B | 1.20B | 52.07M | 6.20M | 4.20M |
| Stockholders Equity | 3.60B | 3.85B | 3.38B | 811.14M | -2.66M | -2.29M |
Cash Flow | ||||||
| Free Cash Flow | -1.49B | -1.29B | -927.25M | -78.37M | -1.46M | -1.77M |
| Operating Cash Flow | -1.36B | -1.01B | -867.38M | -73.52M | -1.46M | -1.77M |
| Investing Cash Flow | -2.44B | -86.20M | -1.25B | -313.86M | 0.00 | 0.00 |
| Financing Cash Flow | 2.75B | 167.56M | 3.15B | 370.57M | 1.66M | 1.48M |
Fischer Medical Ventures Ltd Technical Analysis
Neutral
43.67
Price Trends
37.32
Negative
37.70
Negative
58.80
Negative
Market Momentum
-0.94
Negative
53.52
Neutral
56.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FISCHER, the sentiment is Neutral. The current price of 43.67 is above the 20-day moving average (MA) of 34.93, above the 50-day MA of 37.32, and below the 200-day MA of 58.80, indicating a neutral trend. The MACD of -0.94 indicates Negative momentum. The RSI at 53.52 is Neutral, neither overbought nor oversold. The STOCH value of 56.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:FISCHER.
Fischer Medical Ventures Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹114.27B | 27.36 | ― | 0.44% | 12.51% | 9.82% | |
74 Outperform | ₹97.18B | 17.49 | ― | 0.41% | 4.88% | 66.43% | |
73 Outperform | ₹84.14B | 51.10 | ― | 0.68% | 20.61% | 77.73% | |
65 Neutral | ₹106.83B | 43.96 | ― | 0.16% | 19.57% | 209.85% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ₹23.48B | 75.29 | ― | 0.01% | 178.75% | 2120.65% | |
48 Neutral | ₹58.13B | 31.18 | ― | 0.67% | -13.98% | -31.55% |
* Healthcare Sector Average
IN:FISCHER
Fischer Medical Ventures Ltd
36.20
-51.18
-58.57%
IN:AARTIPHARM
Aarti Pharmalabs Limited
641.25
-228.99
-26.31%
IN:MARKSANS
Marksans Pharma Limited
252.15
-4.99
-1.94%
IN:SHILPAMED
Shilpa Medicare Limited
546.20
56.42
11.52%
IN:STAR
Strides Pharma Science Ltd
1,054.30
167.31
18.86%
IN:THYROCARE
Thyrocare Technologies Ltd
528.65
196.83
59.32%
Fischer Medical Ventures Ltd Corporate Events
Fischer Medical Ventures posts clean FY26 results, appoints new internal auditor and declares dividend
May 31, 2026
Fischer Medical Ventures Ltd has reported its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, with its statutory auditors issuing an unmodified opinion on the accounts. The board also recorded th...
Fischer Medical Ventures Posts FY26 Results, Recommends Dividend and Appoints Internal Auditor
May 29, 2026
Fischer Medical Ventures Ltd has reported its audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026, with statutory auditors issuing an unmodified opinion, underscoring the reliability of its fina...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.